
    
      The study is designed as a combinatorial single-center open-label phase I and II clinical
      study design:

      I. a phase I dose-finding and safety / tolerability study combined with, II. a phase II
      safety / efficacy study on the biological activity of AKS-452 against COVID-19.

      To warrant more extensive development towards a phase III clinical study. The study will have
      a duration of approximately 4 months and will be executed at the University Medical Center
      Groningen, The Netherlands supported by the subsidizing party Akston Biosciences.
    
  